Sign up
Pharma Capital

IXICO PLC reports modest profit in latest half year as it secures additional contracts

IXICO PLC's (LON:IXI) CEO Giulio Cerroni talks Proactive London's Andrew Scott through the neuroscience-focused data analytics group's results for the six months to the end of March 2019.

The firm reported a pre-tax profit on ordinary activities of £106,000, up from a £514,000 loss in the prior year, while revenues jumped to £3.4mln from £2.8mln. Gross margins also rose by 610 basis points to 66.3%.


View full IXI profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.